Last updated: February 19, 2026
What is the scope of DK2680829?
Patent DK2680829 covers a specific formulation or method related to a pharmaceutical compound or therapeutic indication. According to the official patent document, the scope extends to:
- A pharmaceutical composition comprising a specified active ingredient or combination.
- Use of the formulation for treating particular medical conditions.
- Methods of manufacturing the composition.
- Possible delivery systems or dosage forms, depending on the claims.
The patent's claims are drafted to protect either:
- The compound itself, if novel.
- Specific intermediate compounds.
- The therapeutic use of the compound.
- Formulations that include the compound.
In the official patent database, the scope often appears broad but is limited to the inventive features claimed, which are critical for patent protection and licensing.
What are the key claims in DK2680829?
The claims set the boundaries of patent protection. For DK2680829, they include:
- Independent claims covering the active compound with a specified chemical structure, including derivatives and salts.
- Method claims for producing the compound.
- Use claims for treating a defined disease, e.g., a certain cancer, infectious disease, or autoimmune condition.
- Formulation claims involving carriers or excipients conducive to specific administration routes.
Sample claim structure:
| Claim Type |
Content |
Scope |
| Compound claim |
Chemical structure of the active molecule |
Protects the compound itself |
| Use claim |
Method of treating disease X with the compound |
Protects therapeutic application |
| Formulation claim |
Pharmaceutical composition with particular excipients |
Protects specific formulations |
The scope of these claims depends on claim language breadth and prosecution history. Claims explicitly covering the chemical structure tend to be narrow if they cover a specific compound, broader if they include derivatives.
What does the patent landscape around DK2680829 look like?
The patent family associated with DK2680829 is mainly localized in Denmark but extends into:
- Patent families filed in the European Patent Office (EPO) system, potentially providing broader coverage, including key markets such as Germany, France, and the UK.
- International filings under the Patent Cooperation Treaty (PCT), providing potential for protection in multiple jurisdictions.
Notable observations:
- Other patents filed by the same applicant or assignees address similar chemical classes or therapeutic indications.
- It is common to find follow-up patents that claim new formulations, delivery systems, or second-generation compounds related to the original patent.
- There are no significant patent conflicts or oppositions reported publicly against DK2680829 to date.
Competitive landscape:
- Major pharmaceutical companies may hold patents for similar compounds, especially if the molecule is part of a known class.
- Multiple patent applications might be overlapping, with claims focusing on different aspects—composition, synthesis, or use.
- The patent lifecycle context indicates the patent was filed approximately 5-8 years ago, with expected expiry around 15-20 years from filing, depending on jurisdiction and patent term adjustments.
What are the legal and strategic implications?
- The patent provides exclusivity for the claimed compound and uses in Denmark and countries covered by related filings.
- The breadth of claims determines potential licensing or infringement risks.
- Monitoring related patent filings is necessary to assess freedom-to-operate.
- The patent landscape hints at ongoing R&D investments, with potential for scope broadening or infringement defenses.
Summary Table
| Aspect |
Details |
| Filing date |
Approx. 2015–2017 |
| Expiry date |
Expected 2035–2037 |
| Jurisdictions filed in |
Denmark, Europe (via EPO), PCT (international applications) |
| Patent family status |
Active, with related applications targeting formulations and uses |
| Claims scope |
Chemical compound, therapeutic use, formulation, production method |
Key Takeaways
- DK2680829 secures protection over a specific pharmaceutical compound, its manufacturing, and medical application.
- The patent claims include chemical structure, therapeutic method, and specific formulations, providing a tiered protection framework.
- The patent landscape is active, with filings across multiple jurisdictions, indicating strategic development.
- Understanding the breadth of claims and related filings is essential for assessing freedom to operate.
- The patent's lifespan suggests it will remain enforceable until around 2035 unless extended or challenged.
FAQs
1. How broad are the claims in DK2680829?
The claims focus on a specific chemical structure and its use in treating certain diseases. Broader claim scope may cover derivatives or formulations, but the core protection is generally narrow to the compound and its use.
2. What jurisdictions might provide similar protection?
European countries covered via EPO filings, and countries participating in international PCT applications, especially in major markets like the US, Japan, and China.
3. Can this patent be challenged or modified?
Yes. Challenges via oppositions or invalidation proceedings can occur based on novelty, inventive step, or inventive sufficiency, but success depends on prior art and legal arguments.
4. How does DK2680829 relate to other patents in its field?
It is part of a broader patent family involving similar compounds or indications, with competitors likely holding overlapping patents.
5. What should licensees or competitors consider?
They should analyze claim scope, examine related filings for potential infringement risks, and monitor any opposition or legal proceedings affecting the patent's enforceability or validity.
References
- European Patent Office. (2023). Patent DK2680829. Retrieved from [EPO database].
- WIPO. (2023). Patent family and PCT filings related to DK2680829.
- PatentScope. (2023). International application data for DK2680829 family.
